PMID- 33130313
OWN - NLM
STAT- MEDLINE
DCOM- 20211018
LR  - 20240330
IS  - 1525-0024 (Electronic)
IS  - 1525-0016 (Print)
IS  - 1525-0016 (Linking)
VI  - 29
IP  - 2
DP  - 2021 Feb 3
TI  - Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved 
      CAR-T Cell Therapies.
PG  - 433-441
LID - S1525-0016(20)30593-1 [pii]
LID - 10.1016/j.ymthe.2020.10.022 [doi]
AB  - Large B cell lymphoma (LBCL) is curable with standard chemo-immunotherapy in the 
      majority of cases. However, patients with primary refractory or relapsed disease 
      have historically had limited treatment options. Two gene-modified chimeric 
      antigen receptor (CAR)-T cell therapies have now been approved for these 
      indications. The clinical decisions and management surrounding these 
      gene-modified "living drugs" are nuanced and complex. In this article, we discuss 
      the evolving evidence supporting the use of these CAR-T cells, including patient 
      selection, screening procedures, special populations, bridging therapy, 
      lymphodepletion, clinical management, relapse, and follow up.
CI  - Copyright (c) 2020 The American Society of Gene and Cell Therapy. Published by 
      Elsevier Inc. All rights reserved.
FAU - Leick, Mark B
AU  - Leick MB
AD  - Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, 
      Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; 
      Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, 
      USA.
FAU - Maus, Marcela V
AU  - Maus MV
AD  - Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, 
      Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; 
      Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, 
      USA. Electronic address: mvmaus@mgh.harvard.edu.
FAU - Frigault, Matthew J
AU  - Frigault MJ
AD  - Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, 
      Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; 
      Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, 
      USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201031
PL  - United States
TA  - Mol Ther
JT  - Molecular therapy : the journal of the American Society of Gene Therapy
JID - 100890581
RN  - 0 (Receptors, Antigen, T-Cell)
RN  - 0 (Receptors, Chimeric Antigen)
SB  - IM
MH  - Disease Progression
MH  - Drug Approval
MH  - Humans
MH  - *Immunotherapy, Adoptive/methods
MH  - Lymphoma, B-Cell/immunology/*pathology/*therapy
MH  - Neoplasm Staging
MH  - Receptors, Antigen, T-Cell/immunology
MH  - Receptors, Chimeric Antigen/immunology
MH  - T-Lymphocytes/immunology/metabolism
MH  - United States
MH  - United States Food and Drug Administration
PMC - PMC7854294
COIS- Declaration of Interest M.J.F. and M.V.M. have received sponsored research 
      support from Kite Pharma and Novartis and are investigators and consultants on 
      multiple industry-sponsored trials of CAR-T cells. M.V.M. holds equity in Century 
      Therapeutics and TCR2.
EDAT- 2020/11/02 06:00
MHDA- 2021/10/21 06:00
PMCR- 2022/02/03
CRDT- 2020/11/01 20:32
PHST- 2020/09/04 00:00 [received]
PHST- 2020/10/10 00:00 [revised]
PHST- 2020/10/24 00:00 [accepted]
PHST- 2020/11/02 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
PHST- 2020/11/01 20:32 [entrez]
PHST- 2022/02/03 00:00 [pmc-release]
AID - S1525-0016(20)30593-1 [pii]
AID - 10.1016/j.ymthe.2020.10.022 [doi]
PST - ppublish
SO  - Mol Ther. 2021 Feb 3;29(2):433-441. doi: 10.1016/j.ymthe.2020.10.022. Epub 2020 
      Oct 31.